{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:17:54Z","timestamp":1791472674495,"version":"4.3.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple myeloma is an incurable hematologic malignancy, and CAR-T therapy can benefit some patients with relapsed or refractory disease. However, due to individual variations, treatment outcomes vary significantly among different patients. We retrospectively analyzed 77 relapsed\/refractory MM patients receiving BCMA-targeted CAR-T therapy. Baseline and dynamic hematological\/nutritional parameters were assessed at four time points: prior to CAR-T cell collection, before pre-lymphodepletion therapy, before CAR-T cell infusion, and within the 7-day post-infusion. Prognostic groups were stratified by progression-free survival (PFS \u2264 10 vs. &amp;gt; 10 months). The results demonstrate that patients in the poor prognosis group consistently exhibited significantly lower levels of HGB, RBC, and HCT throughout the treatment period(p&amp;lt;0.05). Before pre-lymphodepletion ALB level in the poor prognosis group was significantly lower than that in the good prognosis group (p&amp;lt;0.05). LDH, creatinine, calcium ions, and \u03b22-microglobulin showed no differences at the four observation time points(p&amp;gt;0.05). ROC analysis confirmed prognostic value for HGB (AUC = 0.693), RBC (AUC = 0.669), HCT (AUC = 0.691), and ALB (AUC = 0.756) (all p &amp;lt; 0.05). Kaplan-Meier analysis linked low HGB (\u226492.5 g\/L), RBC (\u22643.26 \u00d710\u00b9\u00b2\/L), HCT (\u226432.05%), and ALB (\u226435.3 g\/L) to inferior PFS (p = 0.011, 0.014, 0.0033, and 0.0001, respectively). Low ALB (\u226435.3 g\/L) before pre-lymphodepletion is a practical biomarker for risk stratification, reflecting compromised bone marrow reserve and immune-nutritional status. These accessible parameters may optimize patient selection and supportive care strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1703394","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:44:49Z","timestamp":1765953889000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic significance of hematological parameters and albumin in BCMA-targeted CAR-T therapy for multiple myeloma"],"prefix":"10.3389","volume":"16","author":[{"given":"Liansheng","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hefei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169071","article-title":"A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed\/refractory multiple myeloma patients treated with CAR-T cells","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:4:243","article-title":"Treatment resistance of solid tumors: role of hypoxia and anemia","volume":"18","author":"Vaupel","year":"2001","journal-title":"MO"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.tracli.2004.11.005","article-title":"Hypoxia and anemia: effects on tumor biology and treatment resistance","volume":"12","author":"Vaupel","year":"2005","journal-title":"Transfusion Clinique Biologique"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e005670","DOI":"10.1136\/jitc-2022-005670","article-title":"Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade","volume":"10","author":"Zheng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12894-018-0427-3","article-title":"Early post-operative serum albumin level predicts survival after curative nephrectomy for kidney cancer: a retrospective study","volume":"18","author":"Tang","year":"2018","journal-title":"BMC Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.05.042","article-title":"Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer","volume":"172","author":"Kim","year":"2022","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26583","article-title":"CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status","volume":"97","author":"Du","year":"2022","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012522","article-title":"Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma","volume":"8","author":"Palacios-Berraquero","year":"2024","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2024.05.020","article-title":"Malnutrition and cachexia are associated with poor CAR T-cell therapy outcomes including survival","volume":"62","author":"Cucchiaro","year":"2024","journal-title":"Clin Nutr ESPEN"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.010","article-title":"Simple score of albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06639-2","article-title":"Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological Malignancies: a retrospective study","volume":"30","author":"Ding","year":"2022","journal-title":"Support Care Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286021","article-title":"Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy","volume":"110","author":"Boardman","year":"2025","journal-title":"Haematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1703394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:44:50Z","timestamp":1765953890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1703394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2025.1703394"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1703394","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1703394"}}